ClinicalTrials.gg
WithdrawnNCT00837291Updated Feb 1, 2018

A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee

A Phase 2 interventional study of CF101 and Placebo in Osteoarthritis of the Knee, sponsored by Can-Fite BioPharma. Withdrawn at 1 site in Israel. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-02-01.

Sponsored by Can-Fite BioPharma · Phase 2, Interventional, and Treatment

Why this study was withdrawn
The company has decided not to conduct the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Osteoarthritis, Knee with a site in Israel — 1 open to participants now, 2 under way, none of them phase 3. Osteoarthritis, Knee · Israel.

Enrollment
24th of 24
0 · median 60
Started
2018
with 1 other
Phase 2
3 of 27
none open now
Registered
9th of 27
by date
Lead sponsor
1 of 27
Can-Fite BioPharma

Among the 27 studies in Osteoarthritis, Knee with a site in Israel, this one is the 24th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 9th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

1 of the 27 studies in Osteoarthritis, Knee with a site in Israel is open now. Recruiting first, the newest first:

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Osteoarthritis, Knee with a site in Israel, or all of them as a file.
02

Study summary

This study will test the effectiveness of CF101 in treating the symptoms of osteoarthritis (OA) of the knee. Eligible patients will be given either CF101 or matching placebo tablets and their symptoms will be evaluated over the 12 week treatment period.

Read the detailed description

This will be a randomized, double-blind, placebo-controlled, parallel-group study in which patients with knee OA will be randomized to either CF101 1 mg or matching placebo tablets every 12 hours and followed for 12 weeks on treatment. For patients with bilateral knee involvement, only 1 knee will be selected for evaluation, namely, the most severely involved knee that meets study criteria (the "index knee"). Screening examinations will occur within 1 month prior to dosing. Washout of non-specific non-steroidal anti-inflammatory drugs (nsNSAIDs) and cyclo-oxygenase-2 (COX-2) inhibitors will occur prior to dosing, and must be followed by requalification before dosing. Disease activity will be assessed using changes from baseline in Patient's Global Assessment (PGA) and Investigator's Global Assessment (IGA) scores, and the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index and subscales for pain, physical function, stiffness, according to the Outcome Measures in Rheumatology Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) criteria. Assessments will take place at Screening, Baseline (Week 0), and at Weeks 2, 4, 8, 12, and 14.

03

Conditions studied

  • Osteoarthritis of the Knee

Keywords

  • osteoarthritis
  • knee
  • CF101
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females age 40 years or above
  • Clinical evidence of knee OA, as indicated by:

    • Pain requiring treatment with NSAID or coxib medication for analgesia for at least 6 months prior to the screening visit, and
    • Pain requiring treatment with NSAID or coxib medication for analgesia on the majority of days during the preceding month
  • Radiographic evidence of knee OA, as indicated by findings of Kellgren-Lawrence Grade 2 or 3 within 1 year prior to the screening visit2
  • American College of Rheumatology functional class I, II, or III3
  • WOMAC pain subscale score ≥40 mm at baseline
  • WOMAC function subscale score >20 mm at baseline
  • PGA >10 mm at baseline
  • In the Investigator's opinion, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol
  • Negative screening serum pregnancy test for female patients of
  • Females of childbearing potential must utilize, throughout the course of the trial, 2 methods of deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method)
  • All aspects of the protocol explained and written obtained

Exclusion criteria

Exclusion Criteria:

  • Predominant patellofemoral disease
  • Concomitant local or systemic inflammatory arthropathy which could confound evaluation of the knee
  • Ipsilateral hip or extremity disease which could confound evaluation of the knee
  • History of clinical significant trauma or surgery to the index knee
  • Arthroscopy to the index knee within 6 months prior to the screening visit
  • , hyaluronic acid, or other intraatricular injection to the index knee within 3 months prior to the screening visit
  • Use of chondroitin sulfate and/or glucosamine, or diacerin, within 2 weeks prior to the screening visit
  • Concomitant requirement for NSAID, coxib medication, or opioid analgesics (acetaminophen is allowed)
  • Use of systemic corticosteroids >10 mg/d of prednisone, or equivalent
  • Presence or history of uncontrolled arterial hypertension or symptomatic hypotension
  • Significant cardiac arrhythmia or conduction block, congestive heart failure, or any other evidence of heart disease; other clinically significant findings on screening (ECG)
  • level \<10.0 gm/dL at the screening visit
  • White blood cell count \<3000/mm3 at the screening visit
  • count \<125,000/mm3 at the screening visit
  • Serum creatinine level outside the central laboratory's normal limits at the screening visit
  • Liver aminotransferase ( and/or AST) levels greater than the at the screening visit
  • Known or suspected immunodeficiency or positivity
  • Pregnancy, lactation, or inadequate as judged by the Investigator
  • Participation in another drug or vaccine trial concurrently or within 30 days prior to screening
  • History of drug or alcohol dependence
  • History of within the past 5 years (excluding excised basal or squamous cell carcinoma of the skin)
  • Diagnosis of Parkinson's Disease
  • Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    CF101 1 mg BID

    Drug: CF101

  • Placebo comparator
    Placebo

    Placebo tablets BID

    Drug: Placebo

Interventions

  • DrugCF101

    CF101 tablets 1 mg BID

    Also known as: IB-MECA

  • DrugPlacebo

    Placebo tablets BID

    Also known as: Inactive tablets

06

What researchers measure

Primary outcomes

  1. Proportion of responders by OMERACT-OARSI definition

    Time frame: 12 weeks

Secondary outcomes

  1. Safety, as assessed through vital signs, physical examinations, adverse event reporting, clinical laboratory testing, and ECGs

    Time frame: 14 weeks

  2. Change from baseline in total WOMAC score, and pain, physical function, and stiffness subscale scores

    Time frame: 12 weeks

  3. Change from baseline in physician's and patient's global assessments

    Time frame: 12 weeks

07

Study locations

1 site
  • Barzilai Medical Center
    Ashkelon, Israel
08

References and documents

Publications

  • Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, Ochaion A, Weinberger A, Fishman P. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol. 2005 Mar;32(3):469-76. PubMed 15742438 ↗
  • Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P. The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs. 2007 Oct;16(10):1601-13. doi: 10.1517/13543784.16.10.1601. PubMed 17922624 ↗
  • van Troostenburg AR, Clark EV, Carey WD, Warrington SJ, Kerns WD, Cohn I, Silverman MH, Bar-Yehuda S, Fong KL, Fishman P. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther. 2004 Oct;42(10):534-42. doi: 10.5414/cpp42534. PubMed 15516022 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2018; primary completion for Dec 2018, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2009
First posted
Feb 5, 2009
StartEst.
Nov 2018
Primary completionEst.
Dec 2018
CompletionEst.
Jan 2019
Last update
Feb 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00837291
Lead sponsor
Can-Fite BioPharma
Responsible party
Sponsor
First posted
Feb 5, 2009
Start date
Nov 2018 (estimated)
Primary completion
Dec 2018 (estimated)
Completion
Jan 2019 (estimated)
Last update
Feb 1, 2018

Study contacts

Michael H Silverman, MD
study director · Can-Fite BioPharma Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CF101

Start the discussion